Company NewsMar 2025
HIBA Pharma Inaugurates New Office at Dubai Science Park
A significant milestone towards becoming a regional leader in specialty pharmaceuticals — marking the expansion of strategic presence in the UAE.
Precision Pharmaceutical Manufacturing — UAE
Hope & Healing
Together, we create a future of hope and healing.
Our Mission
Weengineerprecisionpharmaceuticalsolutionsthatbringlife-savingtherapiestopatientsworldwide.
Uncompromising quality at every stage
About HIBA Pharma
Engineering the Future of Pharmaceutical Care
At Hiba Pharma, we are committed to excellence in oncology pharmaceutical manufacturing. Through cutting-edge technology, rigorous quality standards, and innovative research, we develop life-saving cancer treatments that improve patient outcomes. With a focus on precision, compliance, and accessibility, we strive to set new benchmarks in oncology care. Our mission is clear: to advance pharmaceutical quality and enrich lives by providing safe, effective, and reliable therapies for those who need them most.
At HIBA Pharma, we are the UAE's only manufacturer of sterile injectable oncology medications — a distinction earned through unwavering investment in infrastructure, talent, and international regulatory compliance. Based in KEZAD, Abu Dhabi, our facility is purpose-built to GCC, SFDA, and EDE cGMP standards.
EDE cGMPGCC GMPSFDAISO Standards
16,000M²
State-of-the-art cGMP facility — KEZAD, Abu Dhabi
Our Journey
2021UAE Operations Launched
Launched UAE-based operations with a strategic focus on specialty oncology pharmaceutical manufacturing.
2022Dubai Science Park Headquarters
Established business and R&D headquarters at Dubai Science Park, positioning HIBA at the heart of the UAE's innovation ecosystem.
2023Strategic Licensing Agreements
Secured landmark Licensing & Technology Transfer agreements with Kelix Bio and Novugen Pharma. Groundbreaking ceremony in KEZAD, Abu Dhabi.
2024Construction & Expansion
Licensing & Technology Transfer agreement with SAKAR Healthcare. Civil and structural construction progresses on schedule in KEZAD.
2025MEP & Commissioning
Mechanical, Electrical & Plumbing systems installed and commissioned across all production and clean-room zones.
2026Facility Inauguration
Official facility inauguration with EDE cGMP regulatory approval granted. HIBA Pharma enters full production-ready status.
2027GMP Certifications
Technology transfer phase completion. GMP inspections for GCC and SFDA regulatory markets underway.
Manufacturing Capabilities
End-to-End
Pharmaceutical Manufacturing
From formulation development through sterile fill-finish to final packaging — a vertically integrated manufacturing ecosystem built for the world's most demanding pharmaceutical requirements.
01
Sterile Injectable Manufacturing
Class A/B ISO 5/7 cleanroom environment for oncology injectables. Lyophilization, aseptic fill-finish, and automated visual inspection.
LyophilizationAseptic Fill-FinishISO 5/7
02
Solid Oral Dosage Forms
High-throughput tablet and capsule manufacturing with containment systems for cytotoxic API handling. Capacity exceeding 0.5B units per annum.
TabletsCapsulesCytotoxic Containment
03
Analytical QC Laboratory
Full-service analytical laboratory with HPLC, GC-MS, ICP-MS, and microbiology suite supporting all ICH stability guidelines.
HPLCGC-MSICH Stability
04
Technology Transfer
Regulatory-compliant technology transfer with established partnerships across three continents. Proven from development through commercial scale.
Process ValidationRegulatory FilingsCMC Support
05
Contract Manufacturing
Flexible CMO services — from clinical batches to commercial-scale production for regional and international pharmaceutical companies.
CMOClinical ScaleCommercial Scale
06
Secondary Packaging
Automated serialization, track-and-trace, multi-language labelling, and cold-chain logistics integration at full GMP compliance.
SerializationTrack & TraceCold Chain
Therapeutic Portfolio
Six Domains.
One Standard.
01 / 06
Oncology
Specialized treatments and life-saving sterile injectable cancer therapies that improve patient outcomes. UAE's only local sterile oncology manufacturer.
StatusActive Pipeline
Dosage FormsSterile Injectable, Oral
02 / 06
Critical Care
Essential pharmaceutical solutions addressing critical healthcare challenges with precision formulation and rapid response capabilities.
StatusActive Pipeline
Dosage FormsOral, Topical
03 / 06
Hormone
Advanced hormonal therapies formulated to restore balance and support long-term metabolic and endocrine health.
StatusActive Pipeline
Dosage FormsOral, Topical
04 / 06
Cardiovascular
Next-generation therapies focused on improving cardiovascular health and extending patient longevity.
StatusActive Pipeline
Dosage FormsOral, Topical
05 / 06
CNS
Targeted biologic therapies engineered to modulate the central nervous system with precision and efficacy.
StatusActive Pipeline
Dosage FormsOral, Topical
06 / 06
Metabolic Disorders
Innovative pharmaceutical solutions for complex metabolic and diabetic conditions.
StatusActive Pipeline
Dosage FormsOral, Topical
Manufacturing Excellence
World-Class Facility.
Built for Scale.
16,000M²
Current Facility
Total operational footprint
14,000M²
Expansion Phase
Additional capacity planned
6,150M²
Production Area
cGMP clean-room manufacturing
2,600M²
Warehousing
Temperature-controlled storage
>0.5B
Tablets / Year
Solid oral dosage capacity
>0.25B
Capsules / Year
Hard gelatin capsule output
>40M
Vials / Year
Sterile injectable oncology
>100M
Packs / Year
Final packaged product
Facility Architecture
Six Integrated Operational Zones
Each zone is independently validated, temperature-controlled, and connected via GMP-compliant material flow paths.
01
cGMP Production
6,150M²
02
Sterile Injectable
Class A/BISO 5/7
03
Solid Oral Dosage
Class DISO 8
04
Controlled Warehousing
2,600M²
05
QC Laboratories
Full AnalyticalSuite
06
Critical Utilities
WFI / PurifiedWater Systems
UAE's only sterile injectable oncology manufacturing facility
Location
KEZAD, Abu Dhabi, UAE
Khalifa Economic Zones Abu Dhabi
Global Reach
Manufacturing
in the UAE.
Serving
the World.
Strategically positioned in Abu Dhabi with technology partnerships spanning Canada, Malaysia, and India.
3Continents
5+Technology Partners
GCC+Primary Market
2026Commercial Launch
Loading
Strategic Partnerships
Built on
Shared Vision
HIBA PHARMA actively seeks partnerships with forward-thinking pharmaceutical firms through Licensing, Technology Transfer, and Contract Manufacturing.
Uncompromising Quality
Full cGMP compliance with international standards — FDA, EMA, GCC, and SFDA — ensuring every product meets the highest safety and efficacy benchmarks.
Strategic Investment
State-of-the-art infrastructure backed by top-tier talent and cutting-edge manufacturing technologies purpose-built for complex pharmaceutical challenges.
Operational Efficiency
Optimized processes across the full manufacturing value chain, delivering cost-effectiveness, productivity, and speed-to-market at global scale.
Continuous Innovation
Collaborative R&D partnerships and sustained investment in next-generation formulations to stay ahead of evolving therapeutic landscapes.
Our Partners
Insights
Latest from HIBA Pharma
Read →
PartnershipsNov 2024
Strategic Licensing Agreement with Kelix Bio Expands Oncology Pipeline
HIBA Pharma and Kelix Bio formalize a landmark licensing agreement that significantly expands our oncology pipeline with next-generation targeted therapies.
FacilityJun 2024
Groundbreaking Ceremony at KEZAD Manufacturing Facility
The groundbreaking ceremony at Khalifa Economic Zones Abu Dhabi marks the start of construction on our flagship cGMP manufacturing complex.
Start a Conversation
Ready to Build Something
Extraordinary Together?
Whether you're exploring licensing opportunities, technology transfer, or contract manufacturing — HIBA Pharma has the infrastructure, expertise, and regulatory standing to be your strategic partner.